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Abstract—The reference standard (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone (HG-
10-102-01) and its precursor (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-hydroxyphenyl)(morpholino)methanone (desmethyl-
HG-10-102-01) were synthesized from 2,4,5-trichloropyrimide and 3-methoxy-4-nitrobenzoic acid with overall chemical yield 49% in 
four steps and 14% in five steps, respectively. The target tracer (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-
[11C]methoxyphenyl)(morpholino)methanone ([11C]HG-10-102-01) was prepared from the precursor desmethyl-HG-10-102-01 with 
[11C]CH3OTf through O-[11C]methylation and isolated by HPLC combined with SPE in 45-55% radiochemical yield, based on [11C]CO2 
and decay corrected to end of bombardment (EOB). The radiochemical purity was >99%, and the specific activity (SA) at EOB was 370-
1110 GBq/µmol with a total synthesis time of ~40-minutes from EOB. 
Keywords: [11C]HG-10-102-01; Leucine-rich repeat kinase 2 (LRRK2); Radiosynthesis; Positron emission 
tomography (PET); Parkinson’s disease (PD). 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease of the central nervous system 
(CNS) that mainly affects the motor system in elderly 
people.1-3 The exact cause is still unknown, and thus 
there is presently no cure. Current standards of care 
have serious limitations and largely address only 
symptoms, and the major treatment options are 
medication and surgery to manage PD’s symptoms.4-6 
To discover more effective treatments, a reliable 
diagnostic tool is really needed.7 Neuroimaging of PD is 
one of the most active as well as most challenging areas 
in neuroscience.8,9 Advanced biomedical imaging 
technique positron emission tomography (PET) is a 
promising modality for PD, and significant advances 
have accomplished in this field of molecular imaging.10 
The representative PET tracers used in PD imaging such 
as [18F]FDOPA for dopamine synthesis, [11C]β-CFT for 
dopamine transporter, [11C]DTBZ for vesicular 
monoamine transporter type 2, [11C]raclopride for D2 
receptor, [11C]WAY100635 for serotonin receptor, 
[11C]PBR28 for translocator protein, [11C]PIB for 
aggregated β-amyloid plaques, and [18F]T807 ([18F]AV-
1451) for tau protein are listed in Figure 1.11-16    
The development of new PET imaging probes for in 
vivo detection of PD is critical for early and accurate 
diagnosis and for the successful discovery of disease-
modifying or neuro-protective therapies, as currently 
only symptomatic treatment is available.17-19 Recent 
genetic studies provide new opportunity to discover 
molecularly targeted therapeutics for 
neurodegeneration.20,21 Among the genes associated 
with PD, leucine-rich repeat kinase 2 (LRRK2) is an 
unique enzyme in humans linked to an increased risk of 
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PD, the most common known cause of parkinsonism.22 
LRRK2 has become an attractive therapeutic target for 
PD, and many highly potent, selective, and brain-
penetrable LRRK2 small molecule inhibitors have been 
developed, and the lead compounds HG-10-102-01 ((4-
((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-
methoxyphenyl)(morpholino)methanone), G1023 and 
G7915 exhibited excellent biochemical IC50 values of 
3.2 nM against LRRK2[G2019S], 9 nM against 
pLRRK2, and 9 nM against pLRRK2, respectively.4,5,23-
27 LRRK2 has also become a promising imaging target 
for PD, since the efforts in developing therapeutic 
agents for LRRK2 enzyme have been accompanied by a 
growing interest in translating therapeutic agents to 
diagnostic agents. We are interested in the development 
of new PET agents for PD imaging. In our previous 
works, we have synthesized various PET PD imaging 
agents like [11C]β-CFT, [11C]β-CIT, [11C]raclopride, 
[18F]fallypride, [11C]PBR28, [11C]PIB and [18F]T807.28-
34 In this ongoing effort, we target LRRK2 and develop 
radiolabeled LRRK2 inhibitors as new potential PET 
agents for imaging of LRRK2 enzyme in PD.     
 
N
N
O
O11CH3
CH3O
[11C]PBR28
18F
HO
HO
[18F]FDOPA
O
OH
NH2
NH3C
O
11CH3
O
F
[11C]β-CFT
N
H N
OH
O11CH3
Cl
Cl
O
[11C]Raclopride
N
H311CO
H3CO H
OH
N N
N
11C
N
O
OCH3
[11C]WAY100635
S
N
HN
H311C
OH
[11C]PIB
N
H
N
N18F
[18F]T807 ([18F]AV-1451)
[11C]DTBZ
 
Figure 1. PET tracers for imaging of PD.  
 
The PubMed search showed no records on radiolabeled 
LRRK2 inhibitors. The Google search indicated that 
Genentech has filed a patent entitled fluorine-18 and 
carbon-11 labeled radioligands for positron emission 
tomography (PET) imaging for LRRK2, and several 
radiolabeled LRRK2 inhibitors such as 11C-G1023, 
18FE-G1023, 18FM-G1023, 11C-G7915, 18FE-G7915,  
and 18FM-G7915 have been patented (Figure 2).35 
However, the patented synthesis of radiolabeled LRRK2 
inhibitors is complicated or lacks synthetic details, and 
certain key steps gave poor yield or were difficult to 
reproduce in our hands. On the other hand, HG-10-102-
01 was reported earlier than Genentech compounds 
G1023 and G7915 with simpler chemistry and better 
binding affinity,4,5,23-27 although they have similar 
chemical structures. Here we report the synthesis of a 
new radiolabeled LRRK2 inhibitor [11C]HG-10-102-01 
((4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-
3-[11C]methoxyphenyl)(morpholino)methanone).  
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Figure 2. Fluorine-18 and carbon-11 labeled radioligands for LRRK2.  
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Scheme 1. Synthesis of HG-10-102-01 (4) and desmethyl-HG-10-102-01 
(5). 
 
The reference standard HG-10-102-01 (4)  and its 
demethylated precursor (4-((5-chloro-4-
(methylamino)pyrimidin-2-yl)amino)-3-
hydroxyphenyl)(morpholino)methanone (desmethyl-
HG-10-102-01, 5) were synthesized as depicted in 
Scheme 1.4,5 Commercially available 2,4,5-
trichloropyrimide was regioselectively aminated with 
methylamine in THF to obtain 2,5-dichloro-N-
methylpyrimidin-4-amine (1) in 98% yield. Amide 
derivative 2 was achieved by chlorination of 3-
methoxy-4-nitrobenzoic acid with thionly chloride in 
toluene, followed by amination with morpholine in the 
presence of N,N-diisopropylethylamine (DIPEA) in 
THF in 75% yield. The nitro group of compound 2 was 
reduced by hydrogenation under H2 with 10% Pd/C as 
catalyst in THF and MeOH to afford aniline 3 in 92% 
yield. Amination of compound 1 by trifluoroacetic acid 
(TFA) catalyzed SNAr reaction of aniline 3 in 2-butanol 
gave reference standard 4 in 73% yield. The methoxyl 
 
group of compound 4 was demethylated with BBr3 in 
CH2Cl2 to afford the precursor desmethyl-HG-10-102-
01 (5) in 28% yield. 
 
Synthesis of [11C]HG-10-102-01 ([11C]4) is shown in 
Scheme 2. Desmethyl-HG-10-102-01 underwent O-
[11C]methylation36,37 using the reactive [11C]methylating 
agent [11C]methyl triflate ([11C]CH3OTf)38,39 in 
acetonitrile at 80 °C under basic conditions (2 N 
NaOH). The product was isolated by semi-preparative 
reverse-phase (RP) high performance liquid 
chromatography (HPLC) with a C-18 column, and then 
concentrated by solid-phase extraction (SPE)40,41 with a 
disposable C-18 Light Sep-Pak cartridge to produce the 
corresponding pure radiolabeled compound [11C]4 in 
45-55%  radiochemical yield, decay corrected to end of 
bombardment (EOB), based on [11C]CO2. 
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Scheme 2. Synthesis of [11C]HG-10-102-01 ([11C]4). 
 
The radiosynthesis included three stages: 1) labeling 
reaction; 2) purification; and 3) formulation. We 
employed more reactive [11C]CH3OTf, instead of 
commonly used [11C]methyl iodide ([11C]CH3I),42 in O-
[11C]methylation to improve radiochemical yield of 
[11C]4. We used an Eckert & Ziegler Modular Lab C-11 
Methyl Iodide/Triflate module to produce 
[11C]methylating agent either [11C]CH3OTf or 
[11C]CH3I ([11C]CH3Br passed through a NaI column). 
The direct comparison between [11C]CH3OTf and 
[11C]CH3I confirmed the result. The labeling reaction 
was conducted using a V-vial method. Addition of 
aqueous NaHCO3 to quench the radiolabeling reaction 
and to dilute the radiolabeling mixture prior to the 
injection onto the semi-preparative HPLC column for 
purification gave better separation of [11C]4 from its 
phenyl hydroxyl precursor 5. We used Sep-Pak 
trap/release method instead of rotatory evaporation for 
formulation to improve the chemical purity of 
radiolabeled product [11C]4. In addition, a C18 Light 
Sep-Pak to replace a C18 Plus Sep-Pak allowed final 
product formulation with ≤5% ethanol.43 Overall, it took 
~40 min for synthesis, purification and dose 
formulation.     
 
The radiosynthesis was performed in a home-built 
automated multi-purpose [11C]-radiosynthesis 
module.44-46 This radiosynthesis module facilitated the 
overall design of the reaction, purification and 
reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. In addition, 
the module is designed to allow in-process measurement 
of [11C]-tracer specific activity (SA, GBq/µmol at EOB) 
using a radiation detector at the outlet of the HPLC-
portion of the system. For the reported syntheses, 
product SA was in a range of 370-1110 GBq/µmol at 
EOB. The major factors including [11C]-target and 
[11C]-radiosynthesis unit that affect the EOB SA 
significantly to lead to such a wide range from 370 to 
1110 GBq/µmol have been discussed in our previous 
works.47 The general methods to increase SA have been 
described as well, and the SA of our [11C]-tracers is 
significantly improved.47 The ‘wide range’ of SA we 
reported is for the same [11C]-tracer produced in 
different days, because very different [11C]-target and 
[11C]-radiosynthesis unit situations would make SA in a 
wide range. For a [11C]-tracer produced in the same day, 
the SA of the same tracer in different production runs 
will be in a small range, because [11C]-target and [11C]-
radiosynthesis unit would not be much different in the 
same day. Likewise, the methods to minimize such wide 
range of SA from practice perspective have been 
provided in our previous works.47 At the end of 
synthesis (EOS), the SA of [11C]-tracer was determined 
again by analytical HPLC,48 calculated, decay corrected 
to EOB, and based on [11C]CO2, which was in 
agreement with the ‘on line’ determined value. In each 
our [11C]-tracer production, if semi-preparative HPLC 
was used for purification, then the SA of [11C]-tracer 
was assessed by both semi-preparative HPLC (during 
synthesis) and analytical HPLC (EOS); if SPE was used 
for purification, then the SA of [11C]-tracer was only 
measured by analytical HPLC at EOS.37                
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.48 The chemical purity 
of the precursor and reference standard was >90%. The 
radiochemical purity of the target tracer was >99% 
determined by radio-HPLC through γ-ray (PIN diode) 
flow detector, and the chemical purity of the target 
tracer was >90% determined by reversed-phase HPLC 
through UV flow detector.   
 
ChemOffice 2015 indicated that the Log P for 
desmethyl-HG-10-102-01 and HG-10-102-01 is 1.43 
and 1.7, respectively. We assume the retention time of 
HG-10-102-01 should be longer than the retention time 
of desmethyl-HG-10-102-01 in RP-HPLC. However, 
the precursor has longer retention time than reference 
standard. This atypical elution order is difficult to 
explain, but fortunate from the radiosynthetic 
standpoint, because the radiochemical product eluted 
before the precursor. We experienced the same case 
when we radiosynthesized [11C]β-CIT from Nor-β-CIT 
 
precursor.29 It is important to note that the Log P for 
Nor-β-CIT and β-CIT is 3.31 and 3.69, respectively, 
from ChemOffice 2015.      
 
The experimental details and characterization data for 
compounds 1-5 and for the tracer [11C]4 are given.49  
 
In summary, synthetic routes with moderate to high 
yields have been developed to produce HG-10-102-01, 
desmethyl-HG-10-102-01 and [11C]HG-10-102-01. The 
radiosynthesis employed [11C]CH3OTf for O-
[11C]methylation at the phenyl hydroxyl position of the 
desmethyl precursor, followed by product purification 
and isolation using a semi-preparative RP HPLC 
combined with SPE. [11C]HG-10-102-01 was obtained 
in high radiochemical yield, radiochemical purity and 
chemical purity, with a reasonably short overall 
synthesis time, and high specific activity. This will 
facilitate studies to evaluate [11C]HG-10-102-01 as a 
new potential PET agent for imaging of LRRK2  
enzyme in PD.   
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1.5 Hz, 1H), 6.80 (dd, J = 2.0, 8.0 Hz, 1H), 6.61 (d, J 
= 8.0 Hz, 1H), 5.15 (s, 2H), 3.77 (s, 3H), 3.59-3.57 
(m, 4H), 3.51-3.49 (m, 4H).  
 
(e). (4-((5-Chloro-4-(methylamino)pyrimidin-2-
yl)amino)-3-methoxyphenyl)(morpholino)methanone 
(HG-10-102-01, 4): To a stirred suspension of 
compound 1 (300 mg, 1.68 mmol) in 2-butanol (3 mL) 
was added TFA  (0.3 mL), followed by the addition of 
compound 3 (380 mg, 1.61 mmol). The reaction 
mixture was heated under reflux overnight, and the 
solvent was evaporated in vacuo. The residual was 
diluted with CH2Cl2, washed with saturated aqueous 
NaHCO3 and brine. The organic layer was dried over 
anhydrous Na2SO4 and filtered. The solvent was 
evaporated in vacuo. The crude product was purified 
by silica gel column chromatography with 
CH2Cl2/MeOH (100:5) as eluent to afford 4 as a white 
solid (350 mg, 73%); mp 167-169 °C. 1H NMR 
(DMSO-d6): δ 8.41 (d, J = 8.5 Hz, 1H), 7.96 (s, 1H), 
7.68 (s, 1H), 7.33-7.30 (m, 1H), 7.05 (d, J = 1.5 Hz, 
1H), 7.01 (dd, J = 1.5, 8.0 Hz, 1H), 3.90 (s, 3H), 3.60 
(m, 4H), 3.52 (m, 4H), 2.91 (d, J = 4.5 Hz, 3H). 13C 
NMR (DMSO-d6): δ 169.0, 158.1, 157.4, 152.4, 
147.2, 130.5, 128.0, 119.8, 117.4, 109.8, 104.9, 66.1, 
56.0, 27.7. LC-MS (ESI, m/z): Calcd for 
C17H21ClN5O3 ([M+H]+) 378.1, found: 378.2. HRMS 
(ESI, m/z): Calcd for C17H21ClN5O3 ([M+H]+) 
378.1333, found: 378.1345. 
(f). (4-((5-Chloro-4-(methylamino)pyrimidin-2-
yl)amino)-3-hydroxyphenyl)(morpholino)methanone 
(desmethyl-HG-10-102-01, 5): To a stirred solution of 
compound 4 (345 mg, 0.91 mmol) in anhydrous 
CH2Cl2  (6 mL) was added BBr3 (1.0 M solution in 
CH2Cl2, 4 mL, 4.0 mmol) dropwise at -78 °C under N2 
atmosphere. After the reaction mixture was warmed to 
RT and stirred overnight, it was quenched with ice-
water and neutralized with aqueous 1 N NaHCO3 
solution. The mixture was extracted with CH2Cl2. The 
combined organic layer was washed with brine, dried 
over anhydrous Na2SO4 and filtered. The solvent was 
evaporated in vacuo. The crude product was purified 
by preparative TLC plates with CH2Cl2/MeOH (150:7) 
as eluent to afford 5 as an off-white solid (94 mg, 
28%); mp 213-215 °C. 1H NMR (DMSO-d6): δ 10.4 
(br s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.95 (s, 1H), 7.86 
(s, 1H), 7.34-7.31 (m, 1H), 6.91 (d, J = 2.0 Hz, 1H), 
6.87 (dd, J = 2.0, 8.4 Hz, 1H), 3.59-3.58 (m, 4H), 3.50 
(m, 4H), 2.92 (d, J = 4.4 Hz, 3H). 13C NMR (DMSO-
d6): δ 169.6, 158.6, 158.1, 152.6, 146.1, 130.4, 128.9, 
119.0, 118.8, 114.6, 105.1, 66.7, 28.2. LC-MS (ESI, 
m/z): Calcd for C16H19ClN5O3 ([M+H]+) 364.1, found: 
364.1. HRMS (ESI, m/z): Calcd for C16H19ClN5O3 
([M+H]+) 364.1176, found: 364.1182. 
 (g). (4-((5-Chloro-4-(methylamino)pyrimidin-2-
yl)amino)-3-
[11C]methoxyphenyl)(morpholino)methanone 
([11C]HG-10-102-01, [11C]4): [11C]CO2 was produced 
by the 14N(p,α)11C nuclear reaction in the small 
volume (9.5 cm3) aluminum gas target provided with 
the Siemens RDS-111 Eclipse cyclotron. The target 
gas consisted of 1% oxygen in nitrogen purchased as a 
specialty gas from Praxair, Indianapolis, IN. Typical 
irradiations used for the development were 58 µA 
beam current and 15 min on target. The production 
run produced approximately 25.9 GBq of [11C]CO2 at 
EOB. Desmethyl-HG-10-102-01 (5, 0.1-0.3 mg) was 
dissolved in CH3CN (300 µL). To this solution was 
added aqueous NaOH (2 N, 2 µL). The mixture was 
transferred to a small reaction vial. No-carrier-added 
(high specific activity) [11C]CH3OTf that was 
produced by the gas-phase production method39 within 
12 min from [11C]CO2 through [11C]CH4 and 
[11C]CH3Br with silver triflate (AgOTf) column was 
passed into the reaction vial at RT until radioactivity 
reached a maximum (2 min), and then the reaction vial 
was isolated and heated at 80 °C for 3 min. The 
contents of the reaction vial were diluted with aqueous 
NaHCO3 (0.1 M, 1 mL). The reaction vial was 
connected to a 3-mL HPLC injection loop. The 
labeled product mixture solution was injected onto the 
semi-preparative HPLC column for purification. The 
product fraction was collected in a recovery vial 
containing 30 mL water. The diluted tracer solution 
was then passed through a C-18 Sep-Pak Light 
cartridge, and washed with water (3 × 10 mL). The 
cartridge was eluted with EtOH (3 × 0.4 mL) to 
release the labeled product, followed by saline (10-11 
mL). The eluted product was then sterile-filtered 
through a Millex-FG 0.2 µm membrane into a sterile 
vial. Total radioactivity was assayed and total volume 
(10-11 mL) was noted for tracer dose dispensing. The 
overall synthesis time including HPLC-SPE 
purification and reformulation was ~40 min from 
EOB. The decay corrected radiochemical yield was 
45-55%. Retention times in the analytical HPLC 
system were: tR 5 = 7.87 min, tR 4 = 6.05 min, tR 
[11C]4 = 6.16 min. Retention times in the preparative 
HPLC system were: tR 5 = 17.65 min, tR 4 = 11.32 
min, tR [11C]4 = 11.58 min. 
 
 
